The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma

Journal of the American Academy of Dermatology

Volumn 42, Issue 4, 2000, Pages 606-611

  Acland, K M ^a   O'Doherty, M J ^b   Russell Jones, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0033910298     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.101448     Document Type: Article

References (29)

1. Boyle P, Maisonneuve P, Dore J-F. Epidemiology of malignant melanoma. Br Med Bull 1995;51:523-47.
2. Rigel DS. Malignant melanoma: Incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367-71.
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous malignant melanoma: the Eastern Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
4. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative mapping for early stage melanoma. Arch Surg 1992;127:392-9.
5. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-8.
6. Pijpers R, Collet GJ, Meijer S, Hoekstra OS.The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 1995;22:1238-41.
7. Blessing C, Feine U. Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emmission tomography and ultrasonography. Arch Dermatol 1995;131:1394-8.
8. Lindholm P, Leskinen S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, et al.Carbon-11-methionine PET imaging of malignant melanoma. J Nucl Med 1995;36:1806-10.
9. Steinert HC, Huch Boni RA, Buck A, Boni R, Berthold T, Marincek B, et al. Malignant melanoma: staging with whole body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-9.
10. Rinne D, Baum RP, Hor G, Kaufman R. Primary staging and follow up of high risk melanoma patients with whole body 18F-fluorodeoxyglucose positron emission tomography. Results of a prospective study of 100 patients. Cancer 1998;82:1664-71.
11. Holder WD, White RL, Zuger JH, Easton EJ Jr, Greene FL Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-71.
12. Terhune MH, Swanson N, Johnson M. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998;134:569-72.
13. Au FC, Maier WP, Malmud LS, Goldman LI, Clark WH Jr. Preoperative nuclear scans in patients with melanoma. Cancer 1984;53:2095-7.
14. Evans RA, Bland KI, McMurtrey MJ, Ballantyne AL. Radionuclide scans not indicated for clinical stage 1 melanoma. Surg Gynecol Obstet 1980;150:532-4.
15. Khansur T, Sanders J, Das SK. Evaluation of staging workup in malignant melanoma. Arch Surg 1989;124:847-9.
16. Steinert HC, Huch Boni RA, Buck A, Boni R, Berthold T, Marincek B, et al. Malignant melanoma: staging with whole body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-9.
17. Boni R, Huch Boni RA, Steinert H, Burg G, Buck A, Marincek B, et al. Staging of metastatic melanoma by whole body positron emission tomography using 2-fluorine-18-fluoro-2-Deoxy-D-glucose. Br J Dermatol 1995;132:556-62.
18. Berman C, Reinigen D. Radiologic imaging in malignant melanoma: a review. Semin Surg Oncol 1993;9:232-8.
19. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1995;4:252-8.
20. Critters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
21. Fierlbeck G. Functional staging of melanoma. In: "Perspectives in melanoma II" [abstract]. Proceedings of a conference held in Pittsburgh Pa. Nov 7-8, 1997. p. 23.
22. Boni R, Huch Boni RA, Steinert H, Burg G, Buck A, Marincek B, et al. Staging of metastatic melanoma by whole body positron emission tomography using 2-fluorine-18-fluoro-2-Deoxy-D-glucose. Br J Dermatol 1995;132:556-62.
23. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. Arch Dermatol 1995;131:1394-8.
24. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ. Initial assessment of positron emission tomography for the detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181-9.
25. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
26. Boni R. Whole body positron emission tomography: an accurate staging modality for metastatic melanoma. Arch Dermatol 1996;132:833.
27. Hoh CK, Schiepers C, Seltzer M, Gambhir SS, Silverman DH, Czernin J,et al. PET in oncology: will it replace other modalities? Semin Nucl Med 1997;27:94-106.
28. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
29. Basseres N, Grob LJ, Richard MA, Thinon X, Zarour H, Noe C, et al. Cost effectiveness of surveillance of stage 1 melanoma: a retrospective appraisal based on a 10 year experience in a dermatology department in France. Dermatology 1995;191:199-203.